Regional deposition of mometasone furoate within the nasal cavity
Article Sidebar
Main Article Content
Abstract
The effectiveness of nasal glucocorticoid therapy in the treatment of the inflammation of the nasal mucous membrane depends largely on the preparation used, type of carrier, method of application and thus the target site of drug deposition. Drug sedimentation is of particular importance because of the peculiar and highly diverse structure of the nasal cavity.
Downloads
Article Details
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Shah S.A., Berger R.L., McDermontt J. et al.: Regional deposition of mometasone furoate nasal spray suspension in humans. Allergy Asthma Proc. 2015, 36: 48-57.
3. [http://ec.europa.eu/health/documents/community-register/2015/20150119130440/anx_130440_pl.pdf](wersja: 22.09.2015).
4. [https://www.doz.pl/leki/p3143-Nasonex] (wersja: 22.09.2015).
5. Newman S.P.: Characteristics of radiolabelled versus unlabelled inhaler formulations. J. Aerosol. Med. 1996, 9(suppl. 1): S37-47.
6. Laube B.L.: Devices for aerosol delivery to treat sinusitis. J. Aerosol. Med. 2007, 20: S5-S17; discussion: S17-S18.
7. Vidgren M.T., Kublik H.: Nasal delivery systems and their effect on deposition and absorption. Adv. Drug Deliv. Rev. 1998, 29(1-2): 157-177.
8. Kimbell J.S., Segal R.A., Asgharian B. et al.: Characterization of deposition from nasal spray devices using a computational fluid dynamics model of the human nasal passages. J. Aerosol. Med. 2007, 20(1): 59-74.